Life-Threatening Idiosyncratic Drug-Induced Agranulocytosis in Elderly Patients

被引:0
作者
Emmanuel Andrès
Esther Noel
Jean-Emmanuel Kurtz
Nourredine Henoun Loukili
Georges Kaltenbach
Frédéric Maloisel
机构
[1] Hôpitaux Universitaires of Strasbourg,Department of Internal Medicine
[2] Hôpitaux Universitaires of Strasbourg,Department of Oncology
[3] Hôpitaux Universitaires of Strasbourg,Hematology
[4] Hôpitaux Universitaires de Strasbourg,Department of Internal Medicine and Geriatrics
来源
Drugs & Aging | 2004年 / 21卷
关键词
Septic Shock; Clozapine; Ticlopidine; Agranulocytosis; Dipyrone;
D O I
暂无
中图分类号
学科分类号
摘要
Agranulocytosis is a life-threatening disorder in any age, but particularly so in elderly patients who are receiving, on average, a larger number of drugs than younger patients. Drug-induced agranulocytosis still remains a rare event, with an annual incidence rate of approximately 3–12 cases per million population. This disorder frequently occurs as an adverse reaction to drugs, particularly antibacterials, antiplatelet agents, antithyroid drugs, antipsychotics or antiepileptic drugs, and NSAIDs. Although patients experiencing drug-induced agranulocytosis may initially be asymptomatic, the severity of the neutropenia usually translates into the onset of severe sepsis that requires intravenous broad-spectrum antibacterial therapy. In this setting, haematopoietic growth factors have been shown to shorten the duration of neutropenia. Thus, with appropriate management, the mortality rate of idiosyncratic drug-induced agranulocytosis is now 5–10%. However, given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, physicians should be aware of this complication and its management.
引用
收藏
页码:427 / 435
页数:8
相关论文
共 94 条
[1]  
Schultz W(1922)Ueber eigenartige halserkrankungen Dtsch Med Wochenschr 48 1495-6
[2]  
Andres E(1998)Agranulocytoses médicamenteuses: experience du C.H.R.U. de Strasbourg Sem Hop 74 1005-10
[3]  
Maloisel F(1995)Agranulocytoses aigues médicamenteuses: etude clinique à propos de 30 patients et evolution desétiologies sur 2 décennies Rev Med Interne 16 495-9
[4]  
Offner C(1991)Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes Br J Hematol 79 366-72
[5]  
Paitel JF(2002)Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature Eur J Intern Med 13 324-8
[6]  
Stockemer V(1979)Chronic neutropenia Medicine (Baltimore) 58 128-44
[7]  
Dorvaux V(2002)Non-chemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985–2000) and review of the literature Clin Lab Haematol 24 99-106
[8]  
Julia A(1999)Drug-associated agranulocytosis: experience at Strasbourg Teaching Hospital Arch Intern Med 159 2366-7
[9]  
Olona M(1994)Idiosyncratic drug-induced haematological abnormalities: incidence, pathogenosis, management and avoidance Drug Saf 11 445-62
[10]  
Bueno J(2003)Agranulocytoses medicamenteuses: données actuelles Ann Biol Clin (Paris) 61 121-4